JP2012533595A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012533595A5 JP2012533595A5 JP2012521008A JP2012521008A JP2012533595A5 JP 2012533595 A5 JP2012533595 A5 JP 2012533595A5 JP 2012521008 A JP2012521008 A JP 2012521008A JP 2012521008 A JP2012521008 A JP 2012521008A JP 2012533595 A5 JP2012533595 A5 JP 2012533595A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- beta
- adrenergic receptor
- receptor agonist
- dosage form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 239000000048 adrenergic agonist Substances 0.000 claims 7
- 229940126157 adrenergic receptor agonist Drugs 0.000 claims 7
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 claims 7
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 claims 7
- 239000002552 dosage form Substances 0.000 claims 4
- 238000000338 in vitro Methods 0.000 claims 3
- 238000004090 dissolution Methods 0.000 claims 2
- 239000012530 fluid Substances 0.000 claims 2
- 230000000968 intestinal effect Effects 0.000 claims 2
- 235000012054 meals Nutrition 0.000 claims 2
- 230000036470 plasma concentration Effects 0.000 claims 2
- 229960005105 terbutaline sulfate Drugs 0.000 claims 2
- KFVSLSTULZVNPG-UHFFFAOYSA-N terbutaline sulfate Chemical group [O-]S([O-])(=O)=O.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1 KFVSLSTULZVNPG-UHFFFAOYSA-N 0.000 claims 2
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 claims 1
- 208000013016 Hypoglycemia Diseases 0.000 claims 1
- 230000002218 hypoglycaemic effect Effects 0.000 claims 1
- 230000000422 nocturnal effect Effects 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 239000008363 phosphate buffer Substances 0.000 claims 1
- 229960000195 terbutaline Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0912646.7 | 2009-07-21 | ||
| GBGB0912646.7A GB0912646D0 (en) | 2009-07-21 | 2009-07-21 | Improvements in or relating to organic compounds |
| PCT/EP2010/060326 WO2011009818A1 (en) | 2009-07-21 | 2010-07-16 | Beta 2 adrenergic receptor agonists such as terbutaline for use in the treatment of nocturnal hypoglycemia |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012533595A JP2012533595A (ja) | 2012-12-27 |
| JP2012533595A5 true JP2012533595A5 (enExample) | 2013-09-05 |
| JP6021641B2 JP6021641B2 (ja) | 2016-11-09 |
Family
ID=41058278
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012521008A Expired - Fee Related JP6021641B2 (ja) | 2009-07-21 | 2010-07-16 | 夜間低血糖症の治療にて用いるためのテルブタリンなどのベータ２アドレナリン作動性受容体アゴニスト |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8697755B2 (enExample) |
| EP (1) | EP2456430B1 (enExample) |
| JP (1) | JP6021641B2 (enExample) |
| ES (1) | ES2616322T3 (enExample) |
| GB (1) | GB0912646D0 (enExample) |
| WO (1) | WO2011009818A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1579862A1 (en) | 2004-03-25 | 2005-09-28 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure |
| US8980894B2 (en) | 2004-03-25 | 2015-03-17 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure |
| EP1920785A1 (en) | 2006-11-07 | 2008-05-14 | Boehringer Ingelheim Vetmedica Gmbh | Liquid preparation comprising a complex of pimobendan and cyclodextrin |
| ES2924478T3 (es) | 2012-03-15 | 2022-10-07 | Boehringer Ingelheim Vetmedica Gmbh | Formulación de comprimidos farmacéuticos para el sector médico veterinario, método de producción y uso de los mismos |
| GB201218012D0 (en) * | 2012-10-08 | 2012-11-21 | Jagotec Ag | Dosage forms |
| JP6272475B2 (ja) | 2013-07-19 | 2018-01-31 | ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハーＢｏｅｈｒｉｎｇｅｒ Ｉｎｇｅｌｈｅｉｍ Ｖｅｔｍｅｄｉｃａ ＧｍｂＨ | 防腐エーテル化シクロデキストリン誘導体含有液体水性医薬組成物 |
| CN110721164B (zh) * | 2013-12-04 | 2024-09-17 | 勃林格殷格翰动物保健有限公司 | 匹莫苯的改善的药物组合物 |
| US10537570B2 (en) | 2016-04-06 | 2020-01-21 | Boehringer Ingelheim Vetmedica Gmbh | Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19809719A1 (de) * | 1998-03-06 | 1999-09-09 | Roehm Gmbh | Wäßrige Dispersion geeignet zur Herstellung von Überzugs- und Bindemitteln für feste orale Arzneiformen |
| RU2327450C2 (ru) * | 2002-08-29 | 2008-06-27 | Сипла Лимитед | Фармацевтические продукты и композиции, содержащие специфические антихолинергические средства, агонисты бета-2 и кортикостероиды |
-
2009
- 2009-07-21 GB GBGB0912646.7A patent/GB0912646D0/en not_active Ceased
-
2010
- 2010-07-16 WO PCT/EP2010/060326 patent/WO2011009818A1/en not_active Ceased
- 2010-07-16 JP JP2012521008A patent/JP6021641B2/ja not_active Expired - Fee Related
- 2010-07-16 EP EP10731762.0A patent/EP2456430B1/en not_active Not-in-force
- 2010-07-16 ES ES10731762.0T patent/ES2616322T3/es active Active
- 2010-07-16 US US13/384,388 patent/US8697755B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012533595A5 (enExample) | ||
| JP6637624B2 (ja) | 細菌性膣炎の治療に使用するためのセクニダゾール | |
| RU2012118668A (ru) | Комбинированная терапия с использованием агониста бета 3 адренергического рецептора и антимускаринового средства | |
| WO2011160136A3 (en) | Progesterone containing oral dosage forms and related methods | |
| JP2013529665A5 (enExample) | ||
| JP2019502741A5 (enExample) | ||
| JP2008543936A5 (enExample) | ||
| WO2008122190A1 (en) | The composition comprising l-carnitine or derivatives thereof and its use | |
| CN104758268A (zh) | 一种琥珀酸呋罗曲坦片及其制备方法 | |
| RU2017127509A (ru) | Композиции и способы для улучшенного мышечного метаболизма | |
| IL272834B2 (en) | Amantadine compositions, preparations thereof, and methods of use | |
| JP2007529564A5 (enExample) | ||
| RU2018104691A (ru) | Композиции с модифицированным высвобождением ницерголина | |
| JP2019535830A5 (enExample) | ||
| TWI482632B (zh) | 醫藥用載體及使用該載體的藥物結構 | |
| JP2009522294A5 (enExample) | ||
| CN101040850A (zh) | 秋水仙碱缓释微丸及制备方法 | |
| CN103550182B (zh) | 一种肠溶缓释组合物 | |
| Juan et al. | Preparation and in vivo evaluation of a novel allicin pro-drug tablet | |
| RU2015140567A (ru) | Фармацевтические композиции на основе донепезила, характеризующиеся специфическим профилем растворимости in vitro или фармакокинетическими параметрами | |
| RU2015140501A (ru) | Фармацевтические композиции на основе донепезила, характеризующиеся специфическим профилем растворимости in vitro или фармакокинетическими параметрами | |
| RU2012143550A (ru) | Применение дронедарона или его фармацевтически приемлемой соли для получения лекарственного средства для введения вскоре после прекращения введения амиодарона | |
| KR20150063040A (ko) | 간 질환의 치료에 사용하기 위한 메타독신 및 메타독신 연장 방출성 제제 | |
| TW202430137A (zh) | 甲磺酸雷沙吉蘭口溶膜組合物、其製備方法及用途 | |
| RU2009135418A (ru) | Однофазный фармацевтический композитный препарат (диеногеста и этинилэстрадиола) для пероральной терапии для регулирования артериального давления |